US court has ruled that President Trump overstepped his authority when imposing his tariffs. But an appeals court later suspended the earlier judgment. Stocks also tumbled as investors kept close tabs on a sweeping tax and spending bill that could dramatically increase the federal deficit.
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
Stocks tumbled as sweeping tax and spending bill could dramatically increase federal deficit
Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI)
|
Area |
Company |
Ticker |
Price range $ |
Δ Price |
MktCap $m |
Δ MktCap $m |
|
|
ADC |
ADC Therapeutics |
ADCT |
1.27 – 3.09 |
116 |
% |
306 |
164 |
|
Elevation Oncology |
ELEV |
0.28 – 0.36 |
-19 |
% |
18 |
-4 |
|
|
Mersana Therapeutics |
MRSN |
0.31 – 0.40 |
-21 |
% |
42 |
-12 |
|
|
Sutro Biopharma |
STRO |
0.73 – 1.10 |
-14 |
% |
75 |
-13 |
|
|
IL15 / 2 |
ImmunityBio |
IBRX |
1.89 – 2.90 |
6 |
% |
2 271 |
128 |
|
Mural Oncology |
MURA |
2.51 – 2.98 |
0 |
% |
45 |
0 |
|
|
Nektar Therapeutics |
NKTR |
0.59 – 0.78 |
-9 |
% |
134 |
-14 |
|
|
Werewolf Therapeutics |
HOWL |
0.80 – 1.28 |
34 |
% |
54 |
14 |
|
|
CAR-T |
Allogene Therapeutics |
ALLO |
0.95 – 1.70 |
-30 |
% |
254 |
-111 |
|
Arcellx |
ACLX |
52.80 – 65.55 |
-4 |
% |
3 410 |
-159 |
|
|
Autolus Therapeutics |
AUTL |
1.18 – 1.75 |
24 |
% |
466 |
90 |
|
|
Mustang Bio |
MBIO |
1.09 – 1.34 |
20 |
% |
4 |
1 |
|
|
Other |
Arcus Biosciences |
RCUS |
8.01 – 9.51 |
2 |
% |
945 |
19 |
|
Immutep |
IMMP |
1.67 – 2.49 |
10 |
% |
274 |
25 |
|
|
MacroGenics |
MGNX |
1.36 – 1.75 |
-22 |
% |
86 |
-24 |
|
ADC Therapeutics
ADCT announced further positive data for Zynlonta, a CD19-directed ADC, in combination with Roche’s Columvi (glofitamab) from the Phase 1b LOTIS-7 trial. The new data shows the combination had a 95.5% ORR and 90.9% CR rate in 22 patients with relapsed or refractory DLBCL. The company separately announced that it has terminated the development of ADCT-602, which was in a Phase 1/2 trial in patients with relapsed or refractory B-cell ALL.
Elevation Oncology
Elevation reported net loss for 1Q 2025 of $14 million, compared to $11 million for 1Q 2024. The company also confirmed discontinuation of development of EO-3021 and implementation of a workforce reduction of approximately 70%.
Mersana Therapeutics
Mersana announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company’s cash runway and furthering the development of emiltatug ledadotin, a B7-H4-directed Dolasynthen ADC.
Sutro Biopharma
Sutro announced in its financial results that net loss for 1Q 2025 was $76 million, compared to $58 million for 1Q 2024.
ImmunityBio
ImmunityBio achieved net product revenue of approximately $17 million, representing a 129% increase over $7 million in Q4 2024. Anktiva unit sales volume in Q1 2025 grew 150% over Q4 2024, with monthly volume in March up 69% over February.
Mural Oncology
Short interest of Mural increased by 18 % to 657,864 reported on May 15, compared to 562,784 on April 15.
Nektar Therapeutics
Nektar reported net loss for 1Q 2025 of $51 million, or $0.24 per share, as compared to a net loss of $37 million, or $0.19 per share, in 1Q 2024.
Werewolf Therapeutics
Werewolf announced in its quarterly financial results that net loss was $18 million for the first quarter of 2025, compared to $16 million for the same period in 2024. The company also said that WTX-124 Phase 1/1b trial is on track for data readouts and interactions with the FDA in the second half of the year.
Allogene Therapeutics
Allogene reported a net loss for the first quarter of 2025 of $60 million, or $0.28 per share. The company also announced it will hold an oral presentation of ALLO-316 in kidney cancer and ALPHA3 TIP poster for cema-cel at ASCO Meeting.
Autolus Therapeutics
recommended European Commission approval of obe-cel for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor ALL. Separately, the company announced a net loss of $70 million for 1Q 2025, compared to $53 million for the same period in 2024.
Arcellx
Arcellx announced new positive data for its iMMagine-1 study in patients with relapsed and/or refractory multiple myeloma. Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months. No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel. The data were presented during an oral presentation at EHA 2025.
Mustang Bio
Short interest of Mustang dropped by 70 % to 58,835 reported on May 15, compared to 199,322 on April 30.
Immutep
Immutep announced that the investigator-initiated EFTISARC-NEO Phase 2 trial evaluating efti with radiotherapy plus Keytruda in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded the study’s prespecified median of 35 % tumor hyalinization/fibrosis versus 15 % for historical data from radiotherapy alone in patients with resectable STS.
MacroGenics
MacroGenics reported in its quarterly financial results that a net loss was $41 million for 1Q 2025, compared to a net loss of $52 million for 1Q 2024.
